Form 8-K - Current report:
SEC Accession No. 0001628280-24-047276
Filing Date
2024-11-12
Accepted
2024-11-12 17:03:27
Documents
16
Period of Report
2024-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dna-20241106.htm   iXBRL 8-K 30603
2 EX-99.1 ex991earningspr.htm EX-99.1 278653
7 logoa.jpg GRAPHIC 4122
  Complete submission text file 0001628280-24-047276.txt   503177

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dna-20241106.xsd EX-101.SCH 2196
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dna-20241106_def.xml EX-101.DEF 15988
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dna-20241106_lab.xml EX-101.LAB 28240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dna-20241106_pre.xml EX-101.PRE 16726
19 EXTRACTED XBRL INSTANCE DOCUMENT dna-20241106_htm.xml XML 3377
Mailing Address 27 DRYDOCK AVENUE 8TH FLOOR BOSTON MA 02210
Business Address 27 DRYDOCK AVENUE 8TH FLOOR BOSTON MA 02210 (877) 442-5362
Ginkgo Bioworks Holdings, Inc. (Filer) CIK: 0001830214 (see all company filings)

EIN.: 872652913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40097 | Film No.: 241449668
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)